Einzeltreffer — DigiBib

The present invention is directed to provide a modified CMV gB protein that can induce a group of antibodies including a high ratio of neutralizing antibodies that exhibit a high neutralizing activity against a CMV gB protein, in comparison with a wild type CMV gB, upon induction of immunity and that can be used in the prevention and/or treatment of CMV infection and a CMV vaccine comprising the modified CMV gB protein. The modified CMV gB protein according to the present invention is a modified CMV gB protein having an improved ability to induce body region-recognizing antibodies and comprising modification in a head region.

Titel:	MODIFIED CMV GB PROTEIN AND CMV VACCINE INCLUDING SAME
Link:	View record in USPTO Patent Applications (Volltext)
Veröffentlichung:	2021
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20210346494 Publication Date: November 11, 2021 Appl. No: 17/285874 Application Filed: October 24, 2019 Claim: 1. A modified CMV gB protein comprising a head region modified from a head region in an envelope glycoprotein B (CMV gB protein) in a wild type cytomegalovirus and having an improved ability to induce body region-recognizing antibodies. Claim: 2. The modified CMV gB protein according to claim 1, wherein the modification in the head region comprises modification by a sugar chain introduction. Claim: 3. The modified CMV gB protein according to claim 1, wherein the modification in the head region comprises modification by 2 or more sugar chain introductions. Claim: 4. A The modified CMV gB protein according to claim 1, wherein the modification in the head region comprises modification by sugar chain introductions to at least 2 amino acid residues selected from the group consisting of amino acid residues at corresponding positions to the positions 77, 544, 588, and 609 in the amino acid sequence set forth in SEQ ID NO: 1. Claim: 5. The modified CMV gB protein according to claim 1, wherein the modification in the head region comprises modification by sugar chain introductions to at least 3 amino acid residues selected from the group consisting of amino acid residues at corresponding positions to the positions 77, 544, 588, and 609 in the amino acid sequence set forth in SEQ ID NO: 1. Claim: 6. The modified CMV gB protein according to claim 1, wherein the modification in the head region comprises modification by sugar chain introductions to amino acid residues at corresponding positions to the positions 77, 544, and 588 in the amino acid sequence set forth in SEQ ID NO: 1. Claim: 7. A The modified CMV gB protein according to claim 1, wherein the modification in the head region comprises modification by sugar chain introductions to amino acid residues at corresponding positions to the positions 77, 544, 588, and 609 in the amino acid sequence set forth in SEQ ID NO: 1. Claim: 8. The modified CMV gB protein according to claim 7, wherein the sugar chain is introduced by substitution of an amino acid residue at a corresponding position to the position 77 in the amino acid sequence set forth in SEQ ID NO: 1 with an asparagine residue and substitution of an amino acid residue at a corresponding position to the position 79 in the amino acid sequence set forth in SEQ ID NO: 1 with a threonine residue, substitution of an amino acid residue at a corresponding position to the position 544 in the amino acid sequence set forth in SEQ ID NO: 1 with an asparagine residue and substitution of an amino acid residue at a corresponding position to the position 546 in the amino acid sequence set forth in SEQ ID NO: 1 with a threonine residue, substitution of an amino acid residue at a corresponding position to the position 588 in the amino acid sequence set forth in SEQ ID NO: 1 with an asparagine residue and substitution of an amino acid residue at a corresponding position to the position 589 in the amino acid sequence set forth in SEQ ID NO: 1 with a glycine residue, and substitution of an amino acid residue at a corresponding position to the position 609 in the amino acid sequence set forth in SEQ ID NO: 1 with an asparagine residue, substitution of an amino acid residue at a corresponding position to the position 610 in the amino acid sequence set forth in SEQ ID NO: 1 with a threonine residue, and substitution of an amino acid residue at a corresponding position to the position 611 in the amino acid sequence set forth in SEQ ID NO: 1 with a threonine residue. Claim: 9. The modified CMV gB protein according to claim 1, wherein the modification in the head region comprises a deletion of at least part of the head region. Claim: 10. The modified CMV gB protein according to claim 9, wherein the modification in the head region is a deletion of an entire region of the head region. Claim: 11. The modified CMV gB protein according to claim 1, wherein the modification in the head region comprises substitution of amino acid residues at corresponding positions to the positions 432 and 434 in the amino acid sequence set forth in SEQ ID NO: 1 and wherein the modified CMV gB protein further comprises modification in a body region and the modification in the body region comprises substitution of amino acid residues at corresponding positions to the positions 132, 133, and 216 in the amino acid sequence set forth in SEQ ID NO: 1. Claim: 12. The modified CMV gB protein according to claim 11, wherein the modification in the body region further comprises substitution of an amino acid residue at a corresponding position to the position 215 in the amino acid sequence set forth in SEQ ID NO: 1. Claim: 13. The modified CMV gB protein according to claim 11, wherein the modification in the body region comprises a deletion of amino acid residues at corresponding positions to the positions from 131 to 133 and the positions from 216 to 218 in the amino acid sequence set forth in SEQ ID NO: 1. Claim: 14. A CMV vaccine comprising the modified CMV gB protein according to claim 1. Claim: 15. The modified CMV gB protein according to claim 12, wherein the modification in the body region comprises a deletion of amino acid residues at corresponding positions to the positions from 131 to 133 and the positions from 216 to 218 in the amino acid sequence set forth in SEQ ID NO: 1. Current International Class: 61; 12

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

MODIFIED CMV GB PROTEIN AND CMV VACCINE INCLUDING SAME